BPC-157 Dosage: How Much to Take and How Often

The established BPC-157 dosage range in published preclinical research is 2 mcg/kg to 100 mcg/kg per day, with 10 mcg/kg as the most frequently replicated protocol across independent studies. BPC 157 dosing at 10 mcg/kg appears in tendon repair studies, gut healing models, neurological injury models, and bone healing experiments — it is the closest the literature has to a consensus preclinical dose.

This range comes entirely from rodent and larger-animal studies. The 2025 Pergolizzi orthopaedic systematic review and the Sikiric 2024 mechanism review both summarize the animal literature without identifying a human-equivalent dose, because controlled human trials have not been completed.* Human BPC-157 dosing, where it occurs clinically, is determined by physician evaluation of individual factors — not by direct extrapolation from rodent research.

bpc-157 dosage in mg at the 10 mcg/kg reference: for an 80 kg person, 10 × 80 = 800 mcg = 0.8 mg. That calculation is the foundation for everything in this article.

The BPC-157 dosage chart data below summarizes the dose ranges used in published preclinical research. A BPC 157 dosage chart based on animal studies cannot serve as a treatment protocol — these are research parameters, not clinical instructions. The most replicated dose is 10 mcg/kg/day by injection.

Subcutaneous injection

10 mcg/kg/day is the most commonly studied subcutaneous dose across tendon, muscle, ligament, and bone repair models. Some dose-ranging studies have used 2 mcg/kg (lower bound showing measurable effect) and 100 mcg/kg (used for toxicology comparisons). The subcutaneous route is the most frequently referenced in the orthopedic and musculoskeletal literature.*

Intramuscular injection

10 mcg/kg/day appears in intramuscular protocols as well, particularly in muscle injury and nerve repair studies. The intramuscular route is less frequently described than subcutaneous in the published literature but appears in a subset of neurological models.

Oral administration

Oral BPC-157 dosing in animal studies has used 10 mcg/kg/day delivered by gavage (forced feeding). Several gut healing models — including inflammatory bowel disease, gastric ulcer, and intestinal anastomosis studies — have used this route. The arginate salt form of BPC-157 is specified in some oral protocols because it is more stable in the acidic GI environment than the standard free-acid form.

The BPC 157 dosing chart from the preclinical literature converges on 10 mcg/kg/day across routes and applications. Physicians applying this research to human use do not simply transcribe these figures — they determine dosing based on individual clinical evaluation.

The BPC-157 dosage in mg is derived from body weight: mcg/kg × body weight in kg = total mcg, then divide by 1,000 to convert to mg. The BPC-157 dosage in units on a syringe depends on concentration, not on a fixed conversion factor — "units" is not a standardized measure for peptides the way IU is for insulin.

BPC-157 dosage in mg at 10 mcg/kg

60 kg → 600 mcg (0.60 mg). 70 kg → 700 mcg (0.70 mg). 80 kg → 800 mcg (0.80 mg). 90 kg → 900 mcg (0.90 mg). 100 kg → 1,000 mcg (1.00 mg). These are research reference calculations — a physician determines clinical dosing.

BPC-157 dosage in units on an insulin syringe

On a 100-unit insulin syringe (where 100 units = 1.00 ml), the bpc-157 dosage in units is a volume measurement. The actual mcg delivered per unit depends entirely on the concentration of the reconstituted solution. At 2,500 mcg/ml: 10 units = 0.10 ml = 250 mcg. At 5,000 mcg/ml: 10 units = 0.10 ml = 500 mcg. Always confirm concentration before drawing a dose.

The bpc-157 dosage in ml is a volume that depends on vial size and the amount of bacteriostatic water used for reconstitution. The same mcg dose occupies a different volume at different concentrations. Peptide vials commonly come in two sizes: bpc-157 5mg vials and bpc 157 10mg vials.

5 mg vial

A bpc-157 5mg vial reconstituted with 2 ml of bacteriostatic water yields 2,500 mcg/ml (2.5 mg/ml). To draw 500 mcg from this vial: 500 ÷ 2,500 = 0.20 ml = 20 units on a 100-unit insulin syringe. The same bpc 157 5mg vial reconstituted with 5 ml yields 1,000 mcg/ml (1.0 mg/ml). To draw 500 mcg at this lower concentration: 500 ÷ 1,000 = 0.50 ml = 50 units.

10 mg vial

A bpc 157 10mg vial reconstituted with 2 ml yields 5,000 mcg/ml (5.0 mg/ml). To draw 500 mcg: 500 ÷ 5,000 = 0.10 ml = 10 units. The same bpc 157 10mg vial reconstituted with 4 ml yields 2,500 mcg/ml — the same concentration as the 5 mg/2 ml setup, but with twice the total doses available.

The bpc-157 dosage in ml is therefore not fixed — it is a calculation performed after establishing the vial size and reconstitution volume. Most physicians specify both the target dose in mcg and the reconstitution volume, so the volume per injection can be verified independently.

A BPC-157 dosage calculator performs two sequential calculations: step one, multiply body weight (kg) by the research reference dose (mcg/kg) to get total mcg; step two, divide total mcg by the concentration (mcg/ml) to get volume in ml. That is the complete bpc 157 dosage calculator — two divisions, nothing more.

Worked example

Body weight: 80 kg. Reference dose: 10 mcg/kg. Target dose: 80 × 10 = 800 mcg. Vial: bpc-157 5mg reconstituted in 2 ml (concentration = 2,500 mcg/ml). Volume: 800 ÷ 2,500 = 0.32 ml. On a 100-unit insulin syringe: 32 units. This bpc 157 calculator logic applies to any vial size or concentration — change the concentration value and recalculate.

A BPC-157 dosage calculator is only as accurate as the concentration entered. Errors in reconstitution volume produce proportional errors in every calculated dose. A physician or pharmacist confirms the reconstitution instructions.

A BPC-157 dosage chart by weight maps body weight in kg to dose in mcg, then to volume in ml at a fixed concentration. The chart below uses the 10 mcg/kg research reference dose at two common concentrations. The bpc-157 dosage chart by weight changes with every change in reconstitution volume — the mcg column stays the same; the ml column shifts.

10 mcg/kg, bpc-157 5mg vial in 2 ml (2,500 mcg/ml)

50 kg → 500 mcg → 0.20 ml (20 units). 60 kg → 600 mcg → 0.24 ml (24 units). 70 kg → 700 mcg → 0.28 ml (28 units). 80 kg → 800 mcg → 0.32 ml (32 units). 90 kg → 900 mcg → 0.36 ml (36 units). 100 kg → 1,000 mcg → 0.40 ml (40 units). 110 kg → 1,100 mcg → 0.44 ml (44 units). 120 kg → 1,200 mcg → 0.48 ml (48 units).

10 mcg/kg, bpc 157 10mg vial in 2 ml (5,000 mcg/ml)

50 kg → 500 mcg → 0.10 ml (10 units). 60 kg → 600 mcg → 0.12 ml (12 units). 70 kg → 700 mcg → 0.14 ml (14 units). 80 kg → 800 mcg → 0.16 ml (16 units). 90 kg → 900 mcg → 0.18 ml (18 units). 100 kg → 1,000 mcg → 0.20 ml (20 units). 110 kg → 1,100 mcg → 0.22 ml (22 units). 120 kg → 1,200 mcg → 0.24 ml (24 units).

The higher concentration (10 mg/2 ml) uses smaller injection volumes, which is sometimes preferred for subcutaneous administration.

The BPC-157 half life after subcutaneous or intramuscular injection is estimated at approximately 4 hours, based on pharmacokinetic modeling from rodent studies. The bpc-157 half life has not been directly measured in humans in a controlled pharmacokinetic study. The short BPC-157 half life is one reason some research protocols divide the daily dose into two injections spaced 8–12 hours apart, rather than a single daily dose.

The bpc 157 half life by oral route is different. Oral BPC-157 — particularly the arginate salt form — has a shorter effective absorption window in the GI tract than the injection half life might suggest. For gut-related applications, oral BPC-157 studies have used once- or twice-daily dosing.

The practical implication of the short bpc-157 half life: BPC-157 by injection does not accumulate between doses the way compounds with long half lives do. Plasma levels peak shortly after injection and return toward baseline within a few hours. Whether split dosing produces better tissue-level outcomes than once-daily dosing in humans has not been established in controlled trials.

When to take BPC-157 — morning or evening, pre- or post-workout, with or without food — has not been established in controlled human trials. The research protocols that inform current use are animal studies that specify dose, route, and frequency but rarely specify time of day. Timing guidance for human use is physician-directed.

For injected BPC-157, the most common approach in physician-supervised contexts is once-daily or twice-daily injection at roughly consistent times. The question of when to take bpc 157 by injection is generally not tied to meal timing — subcutaneous peptide absorption is not meaningfully affected by fed or fasted state.

For oral BPC-157 (arginate salt), some protocols use pre-meal dosing for gut-targeted effects, on the basis that contact time with the gastric and intestinal mucosa is maximized in the fasted state. This is practice-based guidance rather than a trial-established finding.

The right answer to when to take BPC-157: as directed by the prescribing physician, based on route of administration, dose, and the specific clinical indication being evaluated.

BPC 157 dosing from the research literature converges on three reference points: 10 mcg/kg/day is the most replicated animal dose; 5 mg and 10 mg are the most common vial sizes; and the BPC-157 half life is approximately 4 hours after injection. Everything else — timing, route, split dosing, reconstitution volume — follows from those anchors and is determined by the physician evaluating the individual.

All bpc-157 dosage figures in this article are drawn from preclinical animal research. They describe what studies have used — not a protocol for human use. For a full discussion of what BPC-157 is, its mechanism, evidence base, and regulatory status, see What Is BPC-157?.

The BPC-157 dosage question has a precise answer for preclinical research — 10 mcg/kg/day in the overwhelming majority of published protocols — and only an approximate one for humans, where controlled dosing trials remain incomplete. A physician evaluation is the appropriate starting point.